Can a percussive breathing machine help meds reach scarred lungs?

NCT ID NCT05366387

Completed Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a device that delivers rapid puffs of air (intrapulmonary percussive ventilation) can help inhaled medication reach scarred lung areas in people with idiopathic pulmonary fibrosis (IPF). Nine participants inhaled a radioactive tracer with and without the device, and imaging measured how much reached fibrotic regions. The goal was to see if the technique is feasible and safe, not to treat the disease itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intrapulmonary percussive ventilation device and 99mTc-DTPA aerosol
What this could lead to: If successful, this could show a way to deliver inhaled drugs more effectively to damaged lung areas in IPF, potentially improving future treatments.
What could go wrong: This is a very small, early feasibility study with only 9 participants, so results may not apply widely. It measures aerosol deposition, not actual treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Pulmonology Department, University Hospital, Tours

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.